DIOVAN
LOE ApproachingNDAORALCAPSULE
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
DIOVAN by Novartis is angiotensin-converting enzyme (ace, kininase ii). Approved for hypertension, to lower blood pressure. First approved in 1996.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIOVAN (generic name: valsartan) is an oral angiotensin II receptor antagonist (ARB) capsule approved in 1996 by Novartis for the treatment of hypertension. It works by selectively blocking angiotensin II binding to the AT1 receptor, preventing vasoconstriction and aldosterone secretion while maintaining independence from ACE pathway inhibition. DIOVAN is often combined with hydrochlorothiazide (a thiazide diuretic) to enhance blood pressure reduction and counteract potassium loss associated with diuretic monotherapy.
$0.0BPart D
Mechanism of Action
angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Valsartan blocks…
Worked on DIOVAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.